Tag:

Endo

Latest Headlines

Latest Headlines

Endo accused of $112M payoff in Opana pay-for-delay suit

Endo Health Solutions tried hard to ward off generic competitors for its big-selling pain med Opana ER. For instance, it petitioned the FDA to block competitors on safety grounds. According to a new lawsuit, Endo also paid off generics maker--and potential rival--Impax Laboratories.

Auxilium says Endo offer not enough to break off with QLT

And so the M&A dance begins. Auxilium Pharmaceuticals today turned its back on a $2.2 billion buyout offer it received last week from Endo Pharmaceutical and said it would stick instead with its plan to merge with Canadian eye-drug maker QLT.

Endo CEO touts 'exciting' $2.2B bid for Auxilium, but his target may not agree

Endo's got a deal for Auxilium Pharmaceuticals in mind. CEO Rajiv De Silva thinks it could be a home run, and analysts seem to agree. Auxilium, however, needs some time to think it over, and it's swallowed a poison pill to make sure it gets just that.

Struggling Endo grabs generics maker DAVA for up to $600M

Endo, in a world of financial hurt, has been turning to M&A lately to ease the pain. Its latest move: a deal for New Jersey generics maker DAVA Pharmaceuticals worth up to $600 million.

Chicago sues J&J, Purdue, Endo, Actavis, Teva over opioid marketing

In the wake of a lawsuit brought by two California counties against five manufacturers of prescription painkillers, the city of Chicago has filed a suit of its own. Chicago is suing the same five pharma companies--alleging, much like California does, that they overstated the benefits of opioid painkillers while deceiving the public about the risks.

Novo, Teva, Shire, Actavis and Mylan post Q1 growth as Endo gets pummeled

Earnings were kind to many of pharma's midsize players between Wednesday and Thursday, with several drugmakers--Endo excluded--posting growth. But not all of those companies reaped the sales they expected to, with Novo Nordisk and Teva falling into that category. Big changes may be in store, however, at least for a few of them--Shire and Mylan, for two, may soon find themselves in the middle of pharma's recent M&A storm.

Zogenix retaining rights to DosePro delivery technology in transaction with Endo

Zogenix is selling its Sumavel DosePro Needle-free Delivery System for migraines to Endo International, but don't be fooled--it is maintaining ownership of the delivery technology upon which the product is based.

UPDATED: Endo finally wins a Low-T drug nod, but safety dispute could snarl its launch

For Endo's testosterone therapy Aveed, the third time wasn't the charm with the FDA--but the fourth time was. After a trio of rejections, the FDA has given the thumbs up to the Low-T drug, and the Malvern, PA-based company expects to launch it this month. But amid the safety questions surrounding testosterone drugs, doing so may not be so easy.

Endo's off-label Lidoderm mantra, whistleblower says: 'Put the patch where the pain is'

For former Endo sales rep Peggy Ryan, the pivotal moment came about three years into her employment with the Malvern, PA-based company. She was at a national meeting, where the topic of discussion was how to distribute off-label studies in an unsolicited way, she says.

Valeant, Endo chalk up new deals with $220M-plus specialty buys

Valeant Pharmaceuticals has added another $250 million deal to its buyout tally, with a $250 million bid to buy Solta Medical, a maker of dermatological treatment devices. And Endo Health Solutions has  agreed to pay up to $220 million for NuPathe and its brand-new migraine treatment Zecuity.